Dr Derek Sloan
Reader/Consultant in Infectious Diseases
Research areas
Dr Sloan is an academic Infectious Diseases clinician, leading his own independent research group at the University of St Andrews. He has worked in both high and low income countries, accruing extensive experience in the management of infectious diseases, particularly tuberculosis (TB), and continues to have extensive collaborative links with partners around the world. His research funding comes from external sources including the Wellcome Trust, UKRI / MRC (UK) and the Europe and Developing Countries Clinical Trial Partnership (EDCTP).
In additional to his role at the University of St Andrews, he works with Radboudumc in The Netherlands as international co-ordinator of UNITE4TB, a large public-private partnership consortium working to develop new treatments for TB, with 30 partner institutions and clinical trials sites 13 countries on 3 continents.
He has supervised 8 successful PhD students, and has five PhD students under current supervision.
Dr Sloan is also a practicing physician in NHS Fife, and has an interest in the acute management of infectious disease outbreaks and has supported humanitarian responses to Ebola Virus Disease (Sierra Leone, 2015 and preparedness deployments to Rwanda in 2018 and 2019), diphtheria (displaced Rohingya population in Bangladesh, 2018), HIV (Ukraine, 2022), and cholera (Malawi, 2023). He is the UK-Med and UK Emegency Medical Team technical referent for Infectious Diseases.
|
Year |
My role |
Funding source |
|
|
2016-2019 |
Co-investigator |
EDCTP HIV/TB diagnostics; a one-stop shop for the same day diagnosis and management of TB and HIV |
|
|
2015-2018 |
Supervisor/ Advisor |
Commonwealth PhD Scholarship/ Epistem Optimizing the Diagnosis and Management of Tuberculosis (TB) and Diabetes Mellitus (DM) among HIV Patients in a high TB and HIV burden setting (student: Rotimi Owolabi) |
|
|
2015-2018 |
Primary Supervisor |
Wellcome Trust Clinical PhD Fellowship awarded to Dr Andrew McCallum |
|
|
2015-2017 |
Principal Investigator |
British Society for Antimicrobial Chemotherapy Effect of MIC distribution on clinical PK-PD modelling to predict treatment outcome in pulmonary TB patients from Blantyre, Malawi |
|
|
2015-2017 |
Principal Investigator |
Wellcome Trust Institutional Strategic Support Fund Grant to LSTM Drug resistance in TB: Microbiological & pharmacological variability influencing outcomes |
|
|
2015-2017 |
Co-investigator |
Wellcome Trust Institutional Strategic Support Fund Grant to LSTM Rational development of an optimal treatment regimen for isoniazid mono-resistant TB |
|
|
2010-2012 |
Co-investigator & collaborator |
Wellcome Trust Masters Training Fellowship awarded to Mr David Mzinza |
|
|
2008-2012 |
Principal Investigator |
Wellcome Trust Clinical PhD Fellowship |
|
|
2008 |
Principal Investigator |
LSTM Equipment Grant (Awarded to set up a mycobacterial liquid culture facility in BSL3 laboratory) |
PhD supervision
- Muge Cevik
- Eva Agnes Laker Odongpiny
- Tionge Sikwese
Selected publications
-
Open access
A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB)
Mlyuka, H. J., Liyoyo, A., Nyaulingo, B., Mpolya, E., Kaswaga, O. L., Semvua, H., Lwambura, S., McHugh, T. D., Wildner, L., Sabiiti, W., Adegbite, B. R., Nliwasa, M., Khosa, C., Mbelele, P., Mbeya, B., Jeremiah, K., Boeree, M. J., Gillespie, S. H., Sloan, D. J. & Mpagama, S. G. & 1 others, , 25 Feb 2026, In: Trials. 27, p. 1-14 14 p., 182.Research output: Contribution to journal › Article › peer-review
-
Comparative assessment of Host transcriptomic- and bacteriological- markers for monitoring treatment response among active tuberculosis patients: a longitudinal study
Nakiboneka, R., Margaritella, N., Nyirenda, T. S., Walbaum, N., Musisi, E., Tionge, S., Nliwasa, M., Msefula, C. L., Williamson, D., Sloan, D. & Sabiiti, W., 8 Jul 2026, (E-pub ahead of print) In: International Journal of Infectious Diseases. p. 108952Research output: Contribution to journal › Article › peer-review
-
Open access
Draft genome sequence of a non-tuberculous Mycobacterium strain isolated from a clinical urine sample
Rivas Ramos, J. E., Johnston, P. R., Hammond, R. J. H., Holden, M. T. G., Sloan, D. J. & Haag, A. F., 28 Jan 2026, In: Access Microbiology. 8, 1, p. 1-4 4 p., 001110.v3.Research output: Contribution to journal › Article › peer-review
-
Open access
Multimorbidity and the risk of post-tuberculosis lung disease: a systematic review and meta-analysis
Hill, K. J., Mbabazi, I., Scopazzini, M. S., Warner, B., Sekaggya Wiltshire, C., Mills, S., Mpagama, S., Stagg, H. R. & Sloan, D. J., 1 Jun 2026, In: BMJ Global Health. 11, 6, p. 1-15 15 p., e020365.Research output: Contribution to journal › Review article › peer-review
-
Open access
Risks and possible implications of weight gain after switch to dolutegravir- in a large Ugandan cohort of people living with HIV
Odongpiny, E. L. A., Otaalo, B., Musaazi, J., Nalugga, E. A., Kiguba, R., Ngabirano, D., Ddungu, A., Owarwo, N., Kesby, M., Holden, M., Castelnuovo, B., Semeere, A., Sloan, D. J. & Sekaggya, C., 7 May 2026, (E-pub ahead of print) In: AIDS. Ahead of PrintResearch output: Contribution to journal › Article › peer-review
-
Open access
Simultaneous measurement of 16S-rRNA and pre-16S-rRNA as a strategy to monitor clinical tuberculosis
Dombay, E., Sabiiti, W., Alferes de Lima Headley, D., Légrády, M. B., van Campen, N., Zweijpfennig, S., Boeree, M. J., Sloan, D. J. & Gillespie, S. H., 8 Apr 2026, In: Frontiers in Antibiotics. 5, 12 p., 1760862.Research output: Contribution to journal › Article › peer-review
-
Open access
The utility of urine lipoarabinomannan as a tuberculosis treatment monitoring tool in people living with HIV
Otaalo, B., Musaazi, J., Nabisere-Arinaitwe, R., Babirye, S., Sloan, D. J., Ssengooba, W., Nakiyingi, L., Reynolds, S. J., Castelnuovo, B., Manabe, Y. C. & Sekaggya-Wiltshire, C., 11 Mar 2026, In: BMC Research Notes. 19, 1, 112.Research output: Contribution to journal › Article › peer-review
-
Open access
Adverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: a retrospective cohort study
Dixon, E. G., Biraua, E., Brencsēns, E., Pašuks, V., Riekstina, V., Šperberga, A., Muckian, M. D., Dear, J. W., Kuksa, L., Sloan, D. J. & Stagg, H. R., 11 Aug 2025, (E-pub ahead of print) In: British Journal of Clinical Pharmacology. Early View, p. 1-10 10 p.Research output: Contribution to journal › Article › peer-review
-
Open access
Analysis of time-to-positivity data in tuberculosis treatment studies: Identifying a new limit of quantification
Dufault, S. M., Davies, G. R., Svensson, E. M., Sloan, D. J., McCallum, A. D., Patel, A., Van Brantegem, P., Denti, P. & Phillips, P. P. J., Feb 2025, In: International Journal of Antimicrobial Agents. 65, 2, p. 1-7 7 p., 107404.Research output: Contribution to journal › Article › peer-review
-
Open access
A programmatic assessment of dolutegravir adverse events and discontinuations in Uganda
Laker Odongpiny, E. A., Nicol, M., Katana, E., Owori, J., Buzibye, A., Sedan, K., Kesby, M., Holden, M., Owarwo, N., Meya, D., Castelnuovo, B., Sloan, D. J. & Sekaggya, C., 24 Jan 2025, (E-pub ahead of print) In: HIV Medicine. Early View, 14 p.Research output: Contribution to journal › Article › peer-review